GlaxoSmithKline plc announced that once-daily Avamys™(fluticasone furoate) nasal spray has been granted marketing authorisation by the European Commission for all 27 European member states, for the treatment of the symptoms of allergic rhinitis in adults, adolescents (12 years and older) and children (6 - 11 years).
(more...)